MTOR and cancer: In light of the mTOR pathway’s upregulation observed in numerous chemoresistant cancers, sirolimus (rapamycin), a first-class mTOR inhibitor, has been revealed to augment apoptosis in human osteosarcoma cells and enhance their responsiveness to anticancer drugs, potentially through the regulation of miRNAs.